Save
Effect of Tumor-Treating Fields plus chemotherapy versus maintenance chemotherapy alone in patients with glioblastoma: A meta-analysis
Author(s): ,
D. Magouliotis
Affiliations:
University Hospital of Larissa, Department of Surgery, Larissa, Greece; Faculty of Medicine, University of Thessaly, Department of Pharmacology, Larissa, Greece
,
E. Asprodini
Affiliations:
Faculty of Medicine, University of Thessaly, Department of Pharmacology, Larissa, Greece
,
K. Svokos
Affiliations:
The Warren Alpert Medical School of Brown University, Department of Neurosurgery, Providence, United States
,
V. Tasiopoulou
Affiliations:
Faculty of Medicine, University of Thessaly, Larissa, Greece
,
V. Papastergiou
Affiliations:
University Hospital of Larissa, Department of Surgery, Larissa, Greece
,
A. Svokos
Affiliations:
Riverside Regional Medical Center, Newport News, United States
S. Toms
Affiliations:
The Warren Alpert Medical School of Brown University, Department of Neurosurgery, Providence, United States
EANS Academy. Papastergiou V. Oct 21, 2018; 225618; EP3002
Dr. Vasileios Papastergiou
Dr. Vasileios Papastergiou
Login now to access Regular content available to all registered users.

Access to Privileged content is currently a membership benefit.

Click here to join EANS or renew your membership.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Background: We aim to review the available literature on patients suffering from glioblastoma treated with Tumor Treating Fields (TTFields) plus chemotherapy or maintenance chemotherapy alone, in order to compare the efficacy and safety of the two methods.
Methods: A systematic literature search was performed in PubMed, Cochrane library and Scopus databases, in accordance with the PRISMA guidelines. Six studies met the inclusion criteria incorporating 1806 patients for the qualitative analysis and 1769 for the quantitative analysis.
Results: Our results reveal increased median overall survival (WMD: 3.29 [95% CI: 2.37, 4.21]; p< 0.00001), survival at one year (OR: 1.81 [95% CI: 1.41, 2.32]; p< 0.00001) and two years (OR: 2.33 [95% CI: 1.73, 3.14]; p< 0.00001), median progression free survival (WMD: 2.35 [95% CI: 1.76, 2.93]; p < 0.00001) along with progression free survival at six months (WMD: 6.86 [95% CI: 5.91, 7.81]; p < 0.00001) for the patients treated with TTFields. Survival at three years was comparable between the two groups. TTFields were associated with fewer adverse events compared to chemotherapy and similar incidence of skin irritation.
Conclusions: TTFields are a feasible and efficient anticancer treatment modality. More randomized controlled studies, with longer follow-up, are necessary to further assess the clinical outcomes and rare complications of TTFields.
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings